Information intended for UK healthcare professionals only.
The production of this Guidelines card has been commissioned by Novartis Pharmaceuticals UK Ltd. See bottom of page for full disclaimer.
1.1 Secukinumab is recommended as an option for treating active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti‑inflammatory drugs (NSAIDs) in adults. It is recommended only if:
- tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and
- the company provides secukinumab according to the commercial arrangement.
1.2 Assess response to secukinumab after 16 weeks of treatment. Continue treatment only if there is clear evidence of response, defined as:
- a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the pre‑treatment value or by 2 or more units and
- a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.
1.3 Take into account any communication difficulties, or physical, psychological, sensory or learning disabilities that could affect responses to the BASDAI and spinal pain VAS questionnaires, and make any appropriate adjustments.
1.4 These recommendations are not intended to affect treatment with secukinumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
- NICE. Secukinumab for treating non-radiographic axial spondyloarthritis. NICE Technology Appraisal Guidance 719. NICE, July 2021. www.nice.org.uk/guidance/ta719
When NICE recommends a treatment, the NHS must make sure it is available to those people it could help, normally within 3 months of the guidance being issued.
MLR ID 147195
Date of preparation: August 2021